A 78-year-old man with obstructive jaundice and osteolytic left scapular tumor was referred to our hospital. Serum carcinoembryonic antigen (CEA), CA19-9, and soluble interleukin 2 receptor were 3.6 IU/L (reference range: 0-5), 128 IU/L (reference range: 0-37), and 2,940 IU/L (reference range: 145-519), respectively. Dynamic contrast-enhanced computed tomography showed a low-density mass in the right anterior segment of the liver and dilation of the left intrahepatic bile duct (Picture 1). We performed a transpapillary biliary biopsy and drainage (Picture 2). Histologically, the tumor was composed of cleaved lymphocytes. A liver needle biopsy confirmed diffuse large B-cell lymphoma (DLBCL) that was positive for CD20 (Picture 3), BCL6, MUM1, and MYC/BCL2 and negative for CD5, CD10, and
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18 FFluorodeoxyglucose-position emission tomography showed no abnormal uptake except for in the liver [maximum standardized uptake value (SUV max) 28] and left scapular tumor (SUV max 3.3) after palliative radiotherapy for bone metastasis. The findings of a bone marrow biopsy were normal. We diagnosed the tumor as primary hepatic DLBCL (NOS, ABC, MYC/BCL2 double expressor). The patient was treated with combination chemotherapy, including pirarubicin, cyclophosphamide, vincristine, and prednisolone following rituximab. Chemotherapy resulted in a partial response via a reduction in the overall tumor size by more than 50% (89.8×58.7 mm to 42×28 mm). The patient was then transferred to another hospital in order to receive further treatments. Primary hepatic lymphoma (PHL) complicated with obstructive jaundice is rare and can mimic a diagnosis of intrahepatic cholangiocellular carcinoma (1) . PHL should be considered in the differential diagnosis of patients presenting with biliary obstruction.
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